Fidelis Capital Partners LLC Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fidelis Capital Partners LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 3,171 shares of the medical research company’s stock after acquiring an additional 25 shares during the period. Fidelis Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,828,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of TMO. Claro Advisors LLC bought a new position in Thermo Fisher Scientific in the first quarter worth about $345,000. Allspring Global Investments Holdings LLC raised its stake in Thermo Fisher Scientific by 40.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 125,565 shares of the medical research company’s stock worth $72,980,000 after buying an additional 36,169 shares in the last quarter. Valeo Financial Advisors LLC raised its stake in Thermo Fisher Scientific by 6.5% in the first quarter. Valeo Financial Advisors LLC now owns 4,031 shares of the medical research company’s stock worth $2,343,000 after buying an additional 247 shares in the last quarter. First Trust Direct Indexing L.P. increased its stake in shares of Thermo Fisher Scientific by 23.4% during the first quarter. First Trust Direct Indexing L.P. now owns 4,981 shares of the medical research company’s stock valued at $2,895,000 after purchasing an additional 945 shares in the last quarter. Finally, Oak Harvest Investment Services bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $266,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Down 0.8 %

Shares of Thermo Fisher Scientific stock opened at $547.90 on Wednesday. The company’s fifty day simple moving average is $602.70 and its 200-day simple moving average is $583.80. The stock has a market capitalization of $209.30 billion, a PE ratio of 34.35, a P/E/G ratio of 3.66 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $420.21 and a 1-year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same quarter in the previous year, the company earned $5.69 EPS. Thermo Fisher Scientific’s revenue for the quarter was up .2% on a year-over-year basis. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on TMO. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Bank of America raised their price target on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 price target for the company. Finally, TD Cowen raised their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.